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Adipogenesis is regulated by a complex network of molecules, including fibroblast growth factors. Keratinocyte growth factor
(KGF) has been previously reported to promote proliferation on rat preadipocytes, although the expression of its specific
receptor, FGFR2-IIIb/KGFR, is not actually detected in mesenchymal cells. Here, we demonstrate that human adipose-derived
stem cells (ASCs) show increased expression of KGF during adipogenic differentiation, especially in the early steps. Moreover,
KGF is able to induce transient activation of ERK and p38 MAPK pathways in these cells. Furthermore, KGF promotes ASC
differentiation and supports the activation of differentiation pathways, such as those of PI3K/Akt and the retinoblastoma
protein (Rb). Notably, we observed only a low amount of FGFR2-IIIb in ASCs, which seems not to be responsible for KGF
activity. Here, we demonstrate for the first time that Neuropilin 1 (NRP1), a transmembrane glycoprotein expressed in ASCs
acting as a coreceptor for some growth factors, is responsible for KGF-dependent pathway activation in these cells. Our study
contributes to clarify the molecular bases of human adipogenesis, demonstrating a role of KGF in the early steps of this process,
and points out a role of NRP1 as a previously unknown mediator of KGF action in ASCs.
1. Introduction
Adipose-derived mesenchymal stem cells (ASCs) represent a
population of self-renewing and multipotent cells that reside
in the vascular stroma of adipose tissue and, when appropri-
ately stimulated, can differentiate into several cell types, that
is, adipocytes, myocytes, chondrocytes, and osteocytes [1].
These cells play important roles in development, post-natal
growth, tissue repair, and regeneration [2, 3]. Based on these
properties, ASCs are a powerful tool not only for regenerative
cell-based therapy but also for investigating the molecular
mechanism involved in adipogenesis.
Adipogenic differentiation has been shown to be regu-
lated by a complex network of transcription factors, cofac-
tors, and signaling intermediates from numerous pathways
that begins with the transient expression of CCAAT/
enhancer binding protein β (CEBPβ) and CEBPδ, which
in turn activate peroxisome proliferator-activated receptor
γ (PPARγ) and CEBPα [4].
Several members of the fibroblast growth factor (FGF)
family have been reported to regulate adipogenesis. In par-
ticular, FGF1 is produced in adipose tissue and acts
through its specific receptor FGFR1 to enhance prolifera-
tion, commitment, and differentiation of preadipocytes
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[5–7]. FGF2 and FGF10 are also expressed in adipose
tissue and have each been implicated in adipogenesis.
FGF2 is regulated through adipogenic differentiation and
displays concentration-dependent biphasic effects on the
expression of adipogenic genes [8, 9]. FGF10 is essential
for the development of adipose tissue, since on the one
hand it stimulates the proliferation of preadipocytes
through the activation of RAS/MAPK pathway [10–12]
and on the other hand it regulates adipogenic differentia-
tion by contributing to the expression of adipogenic genes
such as CEBPβ and PPARγ [13].
KGF, another member of FGFs family, also known as
FGF7, has been also detected in adipose tissue [14, 15].
KGF is produced by cells of mesenchymal origin and
mainly acts in a paracrine way on epithelial cells, playing
an important role in organogenesis, vasculogenesis, and
regeneration of different organs [16, 17] as well as in cel-
lular processes such as proliferation and migration [18,
19]. It is known that KGF acts by binding to the
FGFR2-IIIb receptor, also called KGFR, which is generally
expressed in epithelial cells. Its alternatively spliced iso-
form FGFR2-IIIc, predominantly expressed in cells of the
mesenchymal lineage, usually binds other members of
the FGF family, such as FGF1 and FGF2 [20]. Neverthe-
less, recently it has been reported that KGF is able to pro-
mote proliferation of murine preadipocytes through the
activation of the PI3K-Akt signaling pathway [21]. In
addition, KGF seems to stimulate the expression of key
regulators of adipogenesis, such as CEBPα, CEBPδ, and
sterol-regulatory element binding protein-1 (SREBP-1), in
alveolar type II cells [22]. However, KGF effect on human
ASCs has not been yet investigated.
Moreover, although KGF has been reported to contrib-
ute to preadipocyte proliferation and adipogenesis in an
autocrine manner, the involvement of FGFR2-IIIb in its
action has not been demonstrated, and previous works
suggested that KGF stimulation of preadipocyte prolifera-
tion might happen through an unknown receptor rather
than FGFR2-IIIb [21].
Neuropilin 1 (NRP1) is a transmembrane glycoprotein
that serves as a receptor for various types of ligands, such as
the class 3 semaphorins in neurons, the vascular endothelial
growth factor (VEGF) family in endothelial cells, and the
platelet-derived growth factor (PDGF) in megakaryocytes
[23, 24]. NRP1, although generally considered a coreceptor
for these growth factors, has been observed to induce activa-
tion of some signaling pathways also independently of other
tyrosine kinase receptor expression [25].
Our study has been focused to better define the potential
role of KGF in human adipogenesis by analyzing its expres-
sion during adipogenic differentiation, and in adipose-
derived stem cell proliferation by assessing its effect on the
activation of cellular signaling in ASCs. Then, we analyzed
its mechanism of action, trying to determine the receptor
involved in KGF-mediated stimulation of ASCs.
This work could contribute to a better understanding of
the molecular bases of adipogenesis, and it will also highlight
a previously unknown role of Neuropilin 1 as a mediator of
KGF action in these cells.
2. Materials and Methods
2.1. Adipose Tissue Donors. Subcutaneous adipose tissue
samples were harvested from abdominal wall resections of
seven healthy donors (age range: 22–55 years, BMI range:
18.5–24.9 kg/m2), who underwent elective plastic surgery.
Donors had no systemic diseases or diabetes, and neither
took drugs that could affect the mass of adipose tissue and
metabolism. The deidentified samples were transported to
the laboratory and processed within 24h of collection.
The use of clinical samples of adipose tissue for ASC iso-
lation complied with the Declaration of Helsinki 1975,
revised in 2008, and has been approved by the Institutional
Review Board of the Department of Experimental Medicine
of the Sapienza University of Rome (Ref. 11.1.2/27-10-
2015). Written consent was obtained from all subjects.
2.2. Cell Isolation and Culture. The adipose tissue samples
were transferred into a sterile tube and washed extensively
with sterile phosphate-buffered saline (PBS) containing 2%
PSG to remove contaminating debris and red blood cells.
Then, adipose tissue was transferred into a Petri dish and
digested with 0.075% collagenase (type I; Gibco, Paisley,
UK) in PBS at 37°C for 30–60min, with gentle agitation,
to break down the extracellular matrix. The collagenase
was inactivated with an equal volume of Dulbecco’s mod-
ified Eagle’s medium (DMEM; Gibco) supplemented with
10% fetal bovine serum (FBS), and the suspension was
gently pipetted until disintegration and filtered through a
100μm mesh filter to remove debris. The stromal-vascular
fraction (SVF), which contains ASCs, was then pelleted by
centrifugation for 5min at 2000 rpm. The pelleted cells were
resuspended in DMEM-Ham’s F-12 medium (vol/vol, 1 : 1)
(DMEM/F12; Gibco) supplemented with 20% FBS, 100U/
ml penicillin, 100mg/ml streptomycin, and 2mM L-
glutamine and plated in a 75 cm2 tissue culture flask coated
with collagen (type IV; Sigma-Aldrich, Milan, Italy). The
SVF fraction contains an unpurified population of stromal
cells, which includes ASCs, but also circulating cell types,
hematopoietic stem cells, and endothelial progenitor cells.
ASCs were self-selected out of the SVF during subsequent
tissue culture passages, since they are adherent to the plastic
tissue cultureware.
ASCs were maintained in a 5% CO2 incubator at 37
°C in
a humidified atmosphere, with medium change twice a week.
When reaching 80–90% confluence, cells were detached with
0.5mM EDTA/0.05% trypsin (Gibco) for 5min at 37°C and
replated. ASCs were expanded and cell viability was assessed
by using the trypan blue exclusion assay. Cell morphology
was evaluated by phase contrast microscopy. A homoge-
neous population of ASCs was subsequently checked by ana-
lyzing the surface marker expression profile. For all the
experiments, ASCs were used between passages 2 and 6.
The adenocarcinoma cell lines MCF-7 and MDA-MB-
231 were obtained from the American Type Culture Collec-
tion (ATCC-LGC Promochem, Teddington, UK) and cul-
tured in Dulbecco’s Modified Eagle’s Medium (DMEM;
Invitrogen, Karlsruhe, Germany), supplemented with 10%
fetal bovine serum (FBS; Invitrogen) and antibiotics. Primary
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cultures of human fibroblasts (HFs) were established from
1 cm2 full-thickness skin biopsy from a healthy donor, as pre-
viously described [26], and maintained in DMEM containing
10% FBS.
2.3. Flow Cytometry. Flow cytometric analyses were per-
formed by using a FACSCalibur cytometer (BD Biosciences,
San Jose, CA, USA), as previously described [1]. Briefly, cul-
tured ASCs were harvested, centrifuged, and fixed for 30min
in ice-cold 2% paraformaldehyde. The single-cell suspen-
sions were washed in flow cytometry buffer containing PBS,
2% FBS, and 0.2% Tween 20 and then incubated for 30min
with monoclonal antibodies to CD29, CD34, CD44, CD45,
CD90, and CD166, conjugated to fluorescein isothiocyanate,
phycoerythrin, or phycoerythrin-Cy5 (BD Biosciences). All
monoclonal antibodies were of the IgG1 isotype. Nonspe-
cific fluorescence was determined by incubating the cells
with conjugated mAb anti-human IgG1 (DakoCytomation,
Glostrup, Denmark).
2.4. Multilineage Differentiation. The adipogenic, chondro-
genic, and osteogenic differentiation of cultured ASCs was
achieved using the Human Mesenchymal Stem Cell Func-
tional Identification Kit (R&D Systems, Inc., Minneapolis,
MN, USA), which contains specially formulated media
supplements and a panel of antibodies to define the mature
phenotypes of adipocytes, chondrocytes, and osteocytes, as
previously reported [27]. In particular, for adipogenic differ-
entiation, cells were resuspended in αMEM (Gibco) supple-
mented with 10% FBS, 100U/ml penicillin, 100μg/ml
streptomycin, and 2mM L-glutamine and seeded on cover-
slips onto 24-well plates, at a density of approximately
3.7× 104 cells/well. Medium was replaced every 2-3 days until
100% confluency was reached, then cells were incubated
with adipogenic differentiation medium (ADM, αMEM sup-
plemented with a solution containing hydrocortisone, isobu-
tylmethylxanthine, and indomethacin; R&D Systems), to
induce adipogenesis. In KGF-treated cells, ADM was supple-
mented with 1ng/ml KGF (Upstate Biotechnology, Lake
Placid, NY). The ADM or ADM+KGF was replaced every
3-4 days. The appearance of lipid vacuoles was monitored
by microscopic examination.
2.5. Immunofluorescence Analysis. Immunofluorescence was
performed as previously described [28]. Briefly, cells grown
on coverslips onto 24-well plates were fixed in 4% parafor-
maldehyde for 30min at room temperature, followed by
treatment with 0.1M glycine in PBS for 20min and with
0.1% Triton X-100 in PBS for additional 5min to allow per-
meabilization. Cells were then incubated with the following
primary antibodies: anti-human CD29monoclonal antibody,
anti-human CD166 monoclonal antibody (BioLegend, San
Diego, CA, USA), anti-human CD34 monoclonal antibody
(BD Biosciences), and goat anti-mouse FABP4 antibody
(R&D Systems). After appropriate washing in PBS, primary
antibodies were visualized using FITC-conjugated goat
anti-mouse IgG (Cappel Research Products, Durham, NC,
USA) or Texas Red-conjugated rabbit anti-goat IgG (Jackson
ImmunoResearch Laboratories, West Grove, PA, USA).
For all immunofluorescence experiments, nonspecific
fluorescence was determined by omitting primary antibody.
Nuclei were visualized using 4′,6-diamidino-2-phenylindole
(DAPI) dihydrochloride (Sigma-Aldrich). The single-
stained and merged images were acquired with AxioVision
software (Carl Zeiss, Jena, Germany) using a 20x objective
lens. Quantitative analysis was performed by counting cells
exhibiting FABP4 expression (expressed as percentage of
FABP4-positive cells). More than 50 stained cells per micro-
scopic field were counted. Results from three microscopic
fields, expressed as mean± standard deviation, were reported
in graphs.
2.6. Oil Red O Stain. After 21 days from induction with ADM
or ADM+KGF, cells were fixed in 10% formalin for 30–60
minutes at room temperature, incubated in 60% isopropanol
for 5minutes and stained with oil red O solution, which iden-
tifies lipids, for 5minutes. The images were acquired with
AxioVision software (Carl Zeiss, Jena, Germany) using a
20x objective lens. Subsequently, the stained oil droplets were
treated with isopropanol to elute oil red O dye, and the absor-
bance was quantified at 490nm. Results from three indepen-
dent experiments, expressed as mean± standard deviation,
were reported in a graph.
2.7. MTT Assay. Cells were plated onto 96-well plates at a
density of 2.5× 103 cells/well in DMEM-Ham’s F-12 supple-
mented with 10% FBS, then serum starved for 18 h and
treated or not with 20ng/ml KGF for 1–5 days. Then,
0.5mg/ml MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide; Sigma, St. Louis, MO, USA) was
added, mixed into each well, and incubated at 37°C. After
4 h, the MTT-medium mixture was removed and 100μl
dimethyl sulphoxide (DMSO; Sigma, St. Louis, MO, USA)
was added in each well. The absorbance value was measured
at 490 nm with an ELISA Microplate Reader (Bio-Rad,
Hercules, CA, USA). Results from three independent
experiments, expressed as mean± standard deviation, were
reported in a graph.
2.8. RT-PCR and Quantitative Real-Time PCR (qRT-PCR).
ASCs were harvested and total RNA was extracted with the
use of TRIzol reagent (Invitrogen). cDNAwas generated with
oligo (dT) from 1μg of RNA using the SuperScript III
Reverse Transcriptase Kit (Invitrogen). Specific NRP1 PCR
primers (Table 1) were used, and PCR conditions were as fol-
lows: hold for 2min at 94°C, followed by 40 cycles consisting
of denaturation at 94°C (15 s), annealing at 62°C (30 s), and
elongation at 72°C (20 s). The amplified products were sub-
jected to electrophoresis in a 1.5% agarose gel. GAPDH was
used as a reference gene. Quantitative real-time PCR assays
(qRT-PCR) were conducted in triplicate on an ABI 7500
Real Time instrument (Applied Biosystems) as previously
described [29]. Briefly, the abundance of KGF, FABP4, or
NRP1 was quantified using the appropriate real-time Taq-
Man gene expression assay kit (Applied Biosystems by Life
Technologies, Carlsbad, CA, USA). Cyclophilin A (PPIA)
mRNA was used as endogenous control. For FGFR2-IIIb
and FGFR2-IIIc, specific custom TaqMan primer/probe
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assays were developed and used at a concentration of 1x per
well. Primers and probes are reported in Table 1. The abso-
lute copy number of the target transcripts was obtained
according to a plasmid DNA standard curve, as previously
described [30]. The analysis of the adipogenic differentiation
marker PPARγ was performed using SYBR Green PCR mas-
ter mix kit (Applied Biosystems), and primers were designed
according to Newell et al. [6].
2.9. Immunoprecipitation and Western Blot Analysis. Cells,
treated or not with 20ng/ml KGF for the indicated times,
were lysed in RIPA buffer. For immunoprecipitation experi-
ments, 800μg of lysates were incubated with anti-NRP1 anti-
body overnight at 4°C, and then for 2 h at 4°C with 20μl
Protein A/G PLUS-Agarose (Santa Cruz). Immune com-
plexes were collected by centrifugation and washed three
times with ice-cold RIPA buffer. After a final wash, the super-
natant was discarded and the pellet was resuspended in SDS
lysis buffer, and then boiled in 4x SDS loading dye for 5min.
Proteins were resolved under reducing conditions by 10%
SDS-PAGE and transferred to Immobilon-FL membranes
(Merck Millipore, Billerica, MA, USA). Membranes were
blocked in TBS containing 0.1% Tween 20 (TBS-T) and 5%
milk for 1 h at 25°C and then incubated overnight at 4°C with
the following primary antibodies: anti-Neuropilin 1 (A-12)
and anti-FGF7 (Santa Cruz Biotechnology, Santa Cruz,
CA, USA). Membranes were then incubated with a goat
anti-mouse IgG1 heavy chain- (HRP) conjugated secondary
antibody (Abcam, Cambridge, UK) for 1 h at 25°C. Bound
antibody was detected by enhanced chemiluminescence
detection reagents (Pierce Biotechnology Inc., Rockford,
IL, USA), according to the manufacturer’s instructions.
For Western blot analysis, total proteins (50–150μg) were
resolved under reducing conditions by 7–10% SDS-PAGE
and transferred to Immobilon-FL membranes (Merck
Millipore, Billerica, MA, USA), as previously described
[28]. Membranes were blocked in TBS containing 0.1%
Tween 20 (TBS-T) and 5% milk for 1 h at 25°C and then
incubated overnight at 4°C with the following primary
antibodies: anti-phospho-p44/42 MAPK (Thr202/Tyr204),
anti-phospho-Akt (Ser473), anti-Akt, anti-phospho-p38
MAPK (Thr180/Tyr182), anti-p38 MAPK, anti-phospho-
Rb (Ser807/811), anti-Rb (Cell Signaling Technology Inc.,
Danvers, MA, USA), anti-ERK2, anti-Bek (C-17), anti-
Neuropilin 1 (A-12), anti-FGF7 (Santa Cruz Biotechnology,
Santa Cruz, CA, USA), and anti-β-tubulin (Sigma-Aldrich).
FGFR2-IIIb expression was achieved using a homemade
mouse monoclonal antibody raised against a peptide corre-
sponding to amino acids 314–361 of the human FGFR2-
IIIb [31].
Membranes were then incubated with the appropriate
horseradish peroxidase- (HRP-) conjugated secondary
antibody (Santa Cruz Biotechnology) for 1 h at 25°C. Bound
antibody was detected by enhanced chemiluminescence
detection reagents (Pierce Biotechnology Inc., Rockford, IL,
USA), according to the manufacturer’s instructions. Tubulin
served to estimate the protein equal loading. Densitometric
analysis was performed using Quantity One Program
(Bio-Rad Laboratories S.r.l., Segrate, MI, Italy).
2.10. High-Performance Thin Layer Chromatography
(HPTLC). ASCs untreated or treated with 20 ng/ml KGF for
24 h were lysed in lysis buffer containing 1% Triton X-100,
10mM TRIS-HCl (pH7.5), 150mM NaCl, 5mM EDTA,
1mM Na3VO4, and 75U of aprotinin and allowed to stand
for 20min at 4°C. The cell suspension was mechanically
disrupted by Dounce homogenization (10 strokes). Then,
lysate was centrifuged for 5min at 1300×g to remove nuclei
and large cellular debris. After evaluation of the protein
concentration by Bradford Dye Reagent assay (Bio-Rad,
500-0006), the lysate was subjected to lipid analysis. Neu-
tral lipid extracts were separated by high-performance
thin layer chromatography (HPTLC) using a solvent sys-
tem of hexane/diethyl ether/acetic acid (70 : 30 : 1, v/v/v)
and were detected by staining with 2% copper acetate
solution in 8% phosphoric acid and subsequent heating
at 120°C for 15min. After about 3min, free cholesterol,
cholesterol esters, and triglycerides yielded red spots on
a white background, which were converted into pink-brown
spots after 10min. Quantitative analysis was carried out
using NIH Image1.62 as software (Mac OS X, Apple
Computer International).
2.11. siRNA-Mediated Downregulation of FGFR2 and NRP1.
The FGFR2-specific (siBek) or NRP1-specific (siNRP) short
interfering RNA, which specifically knock down FGFR2 and
Neuropilin 1 gene expression, respectively, as well as nega-
tive control siRNA (siNC), which does not lead to the spe-
cific degradation of any cellular mRNA, were purchased
from Santa Cruz Biotechnology. ASCs were transfected with
siRNA at a final concentration of 25 nM, using the HiPer-
Fect Transfection Reagent (Qiagen, Valencia, CA, USA)
according to the manufacturer’s instructions. Transfected
cells were incubated at 37°C for 48 h before starvation,
treated with 20 ng/ml KGF for 5min at 37°C, and processed
for Western blot assay. The reduction of FGFR2 or NRP1
expression in ASCs was confirmed by immunoblotting.
2.12. Statistical Analysis. Data were analyzed using one-way
analysis of variance (ANOVA) after Bartlett’s test for the
Table 1: List of primers used for the expression analysis of NRP1 by RT-PCR and custom primers/probes used for the expression analysis of
FGFR2-IIIb and FGFR2-IIIc by qRT-PCR.
Gene Forward primer sequence Reverse primer sequence Reporter sequence
NRP1 cctgaatgttcccagaactacacaa caacatcagggaatccatccc —
FGFR2-IIIb ggctctgttcaatgtgaccga gttggcctgccctatataattgga ttccccagcatccgcc
FGFR2-IIIc cacggacaaagagattgaggttct ccgccaagcacgtatattcc ccagcgtcctcaaaag
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homogeneity of variances and Kolmogorov-Smirnov’s test
for the Gaussian distribution and followed by Newman-
Keuls multiple-comparison test or, when appropriate, with
Student’s t-test for paired samples assuming a two-tailed
distribution. All data reported were verified in at least
three different experiments and reported as mean± stan-
dard deviation (SD). Only P values< 0.05 were considered
as statistically significant.
3. Results
3.1. Phenotypic Characterization of ASC Cultures. First, we
obtained primary cultures of ASCs from adipose tissue.
Cultured ASCs showed the typical spindle-shape phenotype
of mesenchymal stem cells, as observed by phase contrast
microscopy (Figure 1(a), A). We then analyzed the specific
pattern of cell surface markers in our ASC cultures by immu-
nofluorescence (Figure 1(a), B–D) and flow cytometry
(Figure 1(b)), in order to exclude the presence of contaminat-
ing elements such as hematopoietic stem cells. ASC charac-
terization was performed using the expression of cell-
specific surface markers, according to the criteria reported
elsewhere [1]. In particular, CD29, CD44, CD73, CD90,
CD105, and CD166 were considered as typical mesenchymal
stemness markers, while CD34 and CD45 were assumed as
expressed by hematopoietic stem cells. Immunofluorescence
analysis confirmed that our cells expressed the CD29 and
CD166 (Figure 1(a), B and C) and were negative for CD34
(Figure 1(a), D). Moreover, flow cytometry on ASCs con-
firmed the expression of CD29, CD44, CD73, CD90,
CD105, and CD166, whereas no expression of CD34 or
CD45 was detected (Figure 1(b)). We also assessed the capa-
bility of ASCs to differentiate into various cell types. The
adipogenic, osteogenic, and chondrogenic differentiation
was induced for 21 days and assessed as previously described
[27]. In particular, cells subjected to adipogenic differentia-
tion showed evident intracellular lipid accumulation,
detected by oil red O staining (Figure 1(c), A) and the expres-
sion of the lineage-specific FABP4 protein (Figure 1(c), B).
ASCs induced towards osteogenic differentiation showed
deposition of de novo bone matrix, as assessed by alizarin
red S staining (Figure 1(c), C), and the expression of the
bone-specific protein osteocalcin (Figure 1(c), D). Finally,
cell pellets induced towards chondrogenic differentiation
showed secretion of sulfated glycosaminoglycans, as indi-
cated by positive stain for Alcian Blue (Figure 1(c), E)
and the expression of the large proteoglycan aggrecan
(Figure 1(c), F). ASCs were further characterized for the
expression of mesenchymal and epithelial markers (vimen-
tin and cytokeratin 14, resp.) by both immunofluorescence
and Western blot analysis, to confirm the absence of epi-
thelial contaminants. Consistently with their mesenchymal
origin, ASCs were positive for vimentin (Figure 1(d), A;
Figure 1(e)), while no expression of cytokeratin 14 (K14)
was detected in our cultures (Figure 1(d), B; Figure 1(e)).
Thus, we were able to obtain primary cultures of ASCs
devoid of contaminating elements, such as hematopoietic
stem cells or epithelial cells.
3.2. KGF Expression during ASC Adipogenesis. To assess the
potential involvement of KGF in adipogenesis, we induced
our cells through adipogenic differentiation by means of a
medium containing specific supplements (ADM) and
assessed the transcript levels of KGF in ASCs on several dif-
ferentiation times (0, 3, 7, 14, and 21 days) by qRT-PCR
(Figure 2(a)). We found that KGF expression fluctuated dur-
ing ASC differentiation, but it was always higher than that in
undifferentiated cells (day 0). In particular, we observed
maximal upregulation in early and late differentiation
(day 3, 1.9-fold increase, P < 0 005, and day 21, 2.0-fold
increase, P < 0 05, resp.). To better characterize the involve-
ment of KGF in the early steps of adipogenesis, we assessed
its expression during the first 3 days of differentiation
(Figure 2(b)), and we observed a peak of KGF expression at
day 1 of adipogenic induction (5.3-fold increase, P < 0 0005),
thus suggesting a potential role of KGF upregulation in
early steps of adipogenesis. We also performed WB analysis
on ASCs at day 0 and at day 21 of adipogenic differentiation,
to assess KGF protein expression (Figure 2(c)). Even at pro-
tein level, differentiated ASCs showed an increase in KGF
expression (2.2-fold), thus confirming the data obtained at
mRNA level by real-time PCR.
3.3. KGF Effect on ASC Proliferation. To determine
whether KGF could also induce ASC proliferation, cells
were serum starved and then treated with KGF for 1, 2,
3, 4, or 5 days, and proliferation was assessed through MTT
assay (Figure 3(a)). No increase in cell number was observed
during the first 2 days, which is compatible with the long
population doubling time of these cells [27]. At 3 and 4 days
of exposure to KGF, we observed a significant induction of
cell proliferation (46%, P < 0 005, and 21%, P < 0 05, resp.),
which is not maintained until day 5, probably due to
KGF degradation.
To assess the mechanism of KGF-mediated proliferation
in ASC cultures, we analyzed the activation of the extracellu-
lar signal-regulated kinase (ERK) pathway and the
p38MAPK pathway. We found a consistent activation of
ERK1/2 after 5 and 30min of treatment with KGF (1.5-fold
and 3.4-fold, resp.; Figure 3(b)). KGF treatment was also able
to strongly phosphorylate the p38 protein at the same time
intervals (5.1-fold and 10.3-fold, resp.; Figure 3(c)), thus sug-
gesting that both these pathways could be involved in KGF-
mediated ASC proliferation.
To better address the involvement of ERK and p38MAPK
pathways in KGF-induced ASC proliferation, we decided to
assess ASC proliferation in the presence of selective inhibi-
tors for these two pathways. First, the efficacy of the ERK
inhibitor U0126 and of the p38MAPK inhibitor SB202190
was confirmed by Western blot analysis of ERK and p38
phosphorylation levels after treatment with KGF in the pres-
ence or not of each inhibitor (Figures 3(d) and 3(e)). As
expected, after 5min of treatment with KGF, we found acti-
vation of ERK1/2 (1.6-fold, P < 0 0005; Figure 3(d) and of
p38 protein (1.8-fold, P < 0 05; Figure 3(e)). Cotreatment
with SB202190 selectively inhibited p38 phosphorylation
(0.8-fold; Figure 3(e)), without affecting ERK phosphoryla-
tion (1.5-fold, P < 0 05; Figure 3(d)). Conversely, treatment
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Figure 1: Phenotypical characterization of ASCs. (a) Representative phase-contrast photomicrograph of ASCs, showing homogeneous,
spindle-shaped morphology (A) and immunofluorescence analysis showing positive staining for the mesenchymal antigens CD29 (B) and
CD166 (C) and negative staining for the hematopoietic CD34 antigen (D). Nuclei (blue) were visualized with 4′,6-diamidino-2-
phenylindole (DAPI). Scale bars: 100 μm. (b) Flow cytometric analysis of ASCs. Cells were stained with monoclonal antibodies directed
against CD29, C44, CD90, CD166, CD73, CD105, CD34, and CD45. Dark grey areas represent patterns obtained with antibodies against
the indicated markers, whereas light grey lines represent the isotype-matched monoclonal antibody that served as a control. Each panel
reported the percentage of positive cells for the corresponding marker. (c) Multilineage differentiation of ASCs. Adipogenic differentiation
was assessed by positive staining with oil red O (A) and by positive immunofluorescence analysis for the adipocyte-specific fatty acid
binding protein 4 (FABP4) (B). Osteogenic differentiation was demonstrated by positive staining for alizarin red (C) and positive
immunofluorescence reactivity to osteocalcin (D). Chondrogenic differentiation was assessed by positive staining for Alcian Blue (E) and
by positive immunofluorescence with anti-aggrecan antibodies (F). (d) Immunofluorescence analysis of ASCs showing positive staining
for the mesenchymal marker vimentin (A) and negative staining for the epithelial marker cytokeratin 14 (K14) (B). Scale bars: 100 μm. (e)
Expression of vimentin and K14 assessed by Western blot analysis on ASC whole cell lysates. HFs and MCF-7 cells were used as controls
for mesenchymal and epithelial lineage, respectively. Western blot with anti-tubulin antibody served as loading control. The images are
representative of at least three independent experiments.
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with U0126 strongly inhibited KGF-mediated ERK phos-
phorylation (0.1-fold, P < 0 0005; Figure 3(d)) without affect-
ing activation of p38 protein (2.3-fold, P < 0 05; Figure 3(e)).
Then, we assessed ASC proliferation. Briefly, cells were
serum starved and then treated for 3 days with KGF alone
or in combination with the ERK inhibitor U0126 or with
the p38MAPK inhibitor SB202190, and proliferation was
assessed through MTT assay (Figure 3(f)). In KGF-treated
cells, we observed a significant induction of cell prolifera-
tion (48%, P < 0 05), as expected. Interestingly, no increase
in cell number was achieved when KGF treatment was
performed in the presence of the p38MAPK inhibitor
SB202190, and even a reduction in cell number was evident
when ASCs were treated with KGF in combination with the
ERK inhibitor U0126 (−35.4%, P < 0 0005), thus confirming
the involvement of both these pathways in KGF-mediated
ASC proliferation.
3.4. KGF Effect on ASC Differentiation.We assessed the effect
of KGF treatment on ASC neutral lipid content. ASCs were
cultured with and without KGF for 24h, and then lipids were
extracted and analyzed by high-performance thin-layer chro-
matography. As reported in Figures 4(a) and 4(b), KGF treat-
ment significantly increased the amount of free cholesterol
(CHOL), triglycerides (TGs), and cholesterol esters (CEs)
(2.0-fold, 3.0-fold, and 1.9-fold, resp., P < 0 005).
We then analyzed the effect of prolonged KGF treat-
ment on ASCs induced to differentiate towards the adi-
pogenic lineage by a standard protocol. At day 21 of
differentiation, cells treated or not with KGF were stained
with oil red O. The quantitation of solubilized oil red O
dye showed that the amount of lipid droplets was higher
in KGF-treated cells with respect to control cells (CTRL)
(2.3-fold, P < 0 005; Figure 4(c)). Cells were also subjected
to immunofluorescence analysis with the adipocyte marker
FABP4 (Figure 4(d)). KGF treatment determined an increase
of the percentage of FABP4-positive cells (30.6% versus
17.9% of untreated cells (CTRL), P < 0 05). Since KGF-
treated ASCs demonstrated enhanced differentiation than
the control cells, we further investigated whether KGF could
regulate the expression of specific genes involved in adipo-
genesis by qRT-PCR. At 21 days of adipogenic differentia-
tion, the expression levels of PPARγ in KGF-treated cells
showed only a slight increase with respect to untreated
cells (CTRL) (1.2-fold; Figure 4(e)), while the levels of FABP4
were significantly higher in KGF-treated cells (6.3-fold,
P < 0 05; Figure 4(f)), thus strengthening the data obtained
with immunofluorescence analysis.
In order to clarify the mechanism by which KGF affects
cell differentiation, we first assessed its effect on sustained
ERK activation, since the activation of differentiation pro-
gram requires the switch off of ERK signaling. We
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Figure 2: qRT-PCR analysis of KGF mRNA expression in ASCs at different times of adipogenic differentiation. (a) Relative KGF mRNA
levels at days 3, 7, 14, and 21 of adipogenic differentiation are shown as fold value of the level of KGF mRNA in undifferentiated cells
(day 0). (b) Relative KGF mRNA levels at days 1, 2, and 3 of adipogenic differentiation are shown as fold value of the level of KGF
mRNA in undifferentiated cells (day 0). Each experiment was performed in triplicate, and mRNA levels were normalized to PPIA
mRNA expression. Error bars represent standard deviations. ∗P < 0 05; ∗∗P < 0 005; and ∗∗∗P < 0 0005. (c) KGF protein expression was
assessed by Western blot analysis with anti-FGF7 antibody on ASC whole cell lysates at days 0 and 21 of adipogenic differentiation.
Tubulin served as loading control.
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Figure 3: Evaluation of KGF effect on ASC proliferation. (a) Proliferation ability of ASCs treated or not with 20 ng/ml KGF for 1–5 days was
determined by MTT assay. Error bars represent standard deviations from three independent experiments. ∗P < 0 05 and ∗∗P < 0 005. (b)
Phosphorylation of ERK was assessed by Western blot analysis with a phospho-specific ERK monoclonal antibody (pERK) on ASC whole
cell lysates, treated or not with 20 ng/ml KGF for 5 and 30min. Levels of total ERK were assessed by blotting with an ERK2-specific
antibody and served as loading control. (c) Phosphorylation of p38 was assessed by Western blot analysis with a phospho-specific p38
monoclonal antibody (pp38) on ASC whole cell lysates, treated or not with 20 ng/ml KGF for 5 and 30min. Levels of total p38 were
assessed by blotting with a p38-specific antibody and served as loading control. (d) Phosphorylation of ERK was assessed by Western blot
analysis with a phospho-specific ERK monoclonal antibody (pERK) on ASC whole cell lysates, treated or not with 20 ng/ml KGF for
5min, in the presence or not of the p38 inhibitor SB202190 or of the ERK inhibitor U0126. Levels of total ERK were assessed by blotting
with an ERK2-specific antibody and served as loading control. (e) Phosphorylation of p38 was assessed by Western blot analysis with a
phospho-specific p38 monoclonal antibody (pp38) on ASC whole cell lysates, treated or not with 20 ng/ml KGF for 30min, in the
presence or not of the p38 inhibitor SB202190 or of the ERK inhibitor U0126. Levels of total p38 were assessed by blotting with a p38-
specific antibody and served as loading control. (b–e) The intensity of the bands was evaluated by densitometric analysis; the values from
at least three independent experiments were normalized and reported as fold increase with respect to the untreated sample. (f)
Proliferation ability of ASCs treated or not with 20 ng/ml KGF in the presence or not of the p38 inhibitor SB202190 or of the ERK
inhibitor U0126 for 3 days was determined by MTT assay. Error bars represent standard deviations from three independent experiments.
∗P < 0 05 and ∗∗∗P < 0 0005.
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Figure 4: Evaluation of KGF effect on ASC adipogenic differentiation. (a) HPTLC analysis of the neutral-lipid cholesterol (CHOL),
triglycerides (TGs), and cholesterol esters (CEs) in ASCs treated or not with 20 ng/ml KGF for 24 h. (b) The intensity of the bands was
evaluated by densitometric analysis, normalized and reported in a graph as relative expression with respect to untreated cells. Error bars
represent standard deviations (∗∗P < 0 005). (c) Representative images of ASCs cultured in adipogenic medium with or without KGF for
21 days and subjected to lipid staining with oil red O. Stained cells were then solubilized using isopropanol, and the extent of adipocyte
differentiation was quantitated by determining the amount of extracted dye, as measured by the optimal absorbance at 490 nM, reported
in the graph as relative expression with respect to untreated cells (∗∗P < 0 005). (d) Immunofluorescence analysis of the adipocyte-specific
fatty acid binding protein 4 (FABP4, red) in ASCs at day 21 of adipogenic differentiation, treated or not with KGF during differentiation.
Nuclei (blue) were visualized with 4′,6-diamidino-2-phenylindole (DAPI). The percentage of FABP4-positive cells was determined by
counting the number of FABP4-positive cells versus total number of cells in ten different areas randomly taken from three independent
experiments. Error bars represent standard deviations (∗P < 0 05). (e) Relative PPARγ mRNA levels at day 21 of adipogenic differentiation
in ASCs treated with KGF are shown as fold value of the level of PPARγ mRNA in untreated cells. Error bars represent standard
deviations. (f) Relative FABP4 mRNA levels at day 21 of adipogenic differentiation in ASCs treated with KGF are shown as fold value of
the level of FABP4 mRNA in untreated cells. Error bars represent standard deviations (∗P < 0 05).
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demonstrated that in ASCs, KGF promotes only transient
ERK activation, with no detection of ERK phosphorylation
after 24 h of KGF treatment (Figure 5(a)).
Then, we decided to examine the effect of KGF on
pathways involved in cell differentiation, such as those
of PI3K/Akt and the retinoblastoma protein (Rb). As
reported in Figure 5(b), KGF was able to induce Akt phos-
phorylation, at both 5 and 30min (1.9-fold and 3.3-fold,
resp.). We also observed in ASCs a significant phosphoryla-
tion of Rb protein induced by KGF after 5min of treatment,
and more consistently after 30min (1.6-fold and 5.3-fold,
resp.; Figure 5(c)).
Taken together, these data demonstrate that KGF is
involved in ASC proliferation and adipogenesis, by pro-
motion of multiple pathways stimulation. Furthermore,
such evidence underscores the presence in these cells of
a membrane receptor that is able to mediate KGF down-
stream signaling.
3.5. Expression and Functionality of FGFR2-IIIb in ASCs.
KGF is known to act by binding to the FGFR2-IIIb isoform
(also known as KGFR), expressed by cells of epithelial ori-
gin, whereas the alternatively spliced FGFR2-IIIc isoform
is generally expressed in mesenchymal cells. We decided
to investigate the expression of both FGFR2 isoforms in
ASCs, through absolute quantification of transcripts by
qRT-PCR. Briefly, using a series of diluted plasmid DNA
as templates, we obtained a standard curve for FGFR2-
IIIb and for FGFR2-IIIc, from which we obtained the
exact copy number of both isoforms in ASCs, as well as
in human fibroblasts (HFs), used as control for the mesen-
chymal lineage, and in the human breast cancer cell line
MCF-7, used as control for the epithelial lineage
(Figure 6(a)). As expected, we observed a high expression
of the mesenchymal isoform FGFR2-IIIc in both ASCs
and HFs (about 2263 and 2302 copies/25 ng total RNA,
resp.), and a strong expression of FGFR2-IIIb in the epi-
thelial cell line MCF-7 (3768 copies), which also express
a small amount of FGFR2-IIIc (482 copies), due to their
neoplastic nature, as previously observed [32, 33]. HFs did
not express a significant amount of FGFR2-IIIb (16 copies),
but, surprisingly, we detected a certain amount of this iso-
form in ASCs (252 copies).
Therefore, to assess if the presence of FGFR2-IIIb tran-
script in these cells would correspond to a significant amount
of protein, we performed Western blot analysis on the same
cellular models. Western blot with a commercial antibody
directed against FGFR2 (Bek), which does not discriminate
the two isoforms FGFR2-IIIb and FGFR2-IIIc, showed a
consistent expression of FGFR2 protein in all the three type
of cells (Figure 6(b)). Then, we assessed FGFR2-IIIb expres-
sion by using a homemade antibody [31], which is able to
specifically recognize this isoform. As shown in Figure 6(b),
Western blot analysis for FGFR2-IIIb confirmed a consistent
expression in MCF-7 cells and an almost undetectable
expression in HFs. However, we detected a faint but not
negligible expression of FGFR2-IIIb in ASCs, thus con-
firming the data obtained by qRT-PCR.
These results demonstrate for the first time that ASCs,
despite their mesenchymal nature, are able to synthesize
and express a low amount of FGFR2-IIIb mRNA and protein.
So, we wondered if this low amount of FGFR2-IIIb in
ASCs would be sufficient to support KGF-mediated pathway
activation in these cells. For this purpose, we achieved the
downmodulation of FGFR2 gene expression in ASCs by
transfection with an FGFR2-specific small interfering RNA
(siBek). A nonspecific siRNA was used as negative control
(siNC). First, we analyzed the efficiency of FGFR2 silencing
by Western blot with Bek polyclonal antibodies in ASCs
treated or not with KGF for 5min at 37°C. Tubulin was used
to assess the equal loading (Figure 7(a)). SiBek specifically
reduced FGFR2 expression by more than 80%, in both
untreated (CTRL) and KGF-treated cells (0.1- and 0.2-fold
increase, resp., P < 0 005), with respect to treatment of cells
with control siRNA (siNC) (Figure 7(a)). It should be noticed
that KGF treatment induced a decrease in FGFR2 protein
levels, probably due to receptor endocytosis and lysosomal
degradation (see Figure S1 for time course experiments).
Then, we investigated the effect of FGFR2 downregula-
tion on ERK activation induced by KGF. As shown in
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Figure 5: Evaluation of differentiation pathway activation by KGF. (a) Sustained phosphorylation of ERK was assessed by Western blot
analysis with a phospho-specific ERK monoclonal antibody (pERK) on ASC whole cell lysates, treated or not with 20 ng/ml KGF for 24 h.
Levels of total ERK were assessed by blotting with an ERK2-specific antibody and served as loading control. (b) Phosphorylation of Akt
was assessed by Western blot analysis with a phospho-specific Akt monoclonal antibody (pAkt) on ASC whole cell lysates, treated or not
with 20 ng/ml KGF for 5 and 30min. Levels of total Akt were assessed by blotting with an Akt-specific antibody and served as loading
control. (c) Phosphorylation of Rb was assessed by Western blot analysis with a phospho-specific Rb monoclonal antibody (pRb) on ASC
whole cell lysates, treated or not with 20 ng/ml KGF for 5 and 30min. Levels of total Rb were assessed by blotting with a Rb-specific
antibody and served as loading control. The images are representative of at least three independent experiments.
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Figure 7: Effect of FGFR2 silencing on KGF-mediated phosphorylation of ERK. (a) ASCs transfected with FGFR2-specific siRNA (siBek) or
nonspecific control siRNA (siNC), treated or not with 20 ng/ml KGF for 5min at 37°C, were lysed, and FGFR2 expression was analyzed by
immunoblotting with anti-Bek antibodies. siBek induced a marked reduction in FGFR2 expression in both untreated and KGF-treated cells.
Western blot with anti-tubulin antibodies was used as loading control. (b) The same lysates were analyzed by immunoblotting with anti-
phospho-ERK antibody. Transfection with siBek did not affect ERK phosphorylation levels in KGF-treated cells. The levels of total ERK
were assessed by Western blot with anti-ERK1/2 antibodies. The intensity of the bands was evaluated by densitometric analysis; the values
from a representative experiment were normalized, expressed as fold increase with respect to the untreated siNC sample and reported as a
graph. ∗∗P < 0 005 and ∗∗∗P < 0 0005.
11Stem Cells International
Figure 7(b), transfection of ASCs with FGFR2 siRNA did not
lead to a significant reduction in ERK phosphorylation
induced by KGF (1.7-fold for siBek versus 1.6-fold for siNC),
thus suggesting that KGF activity in these cells is not carried
out through FGFR2-IIIb, but is presumably mediated by a
previously hypothesized unknown receptor.
3.6. Identification of a Potential Alternative Receptor for
KGF in ASCs. In order to find another receptor that might
be responsible for KGF pathway activation in ASCs, we
analyzed the KGF Entrez Gene database [34]. The first
interactant gene reported in the “Interactions” section was
Neuropilin 1 (NRP1), a known coreceptor for other growth
factors, such as VEGF-A or PDGF. Such interaction has been
demonstrated by West et al. [35].
We first assessed that NRP1 is expressed in ASCs, both at
the RNA and protein level (Figures 8(a) and 8(b), resp.).
MDA-MB-231 cells were used as positive control for Neuro-
pilin expression. Then, to determine whether the NRP1
receptor was in a molecular complex with the KGF protein,
the ability of KGF to coprecipitate with the NRP1 receptor
was assessed in ASCs treated or not with 20 ng/ml KGF for
5min. Protein lysates were immunoprecipitated with anti-
NRP1 antibody, and the immunoprecipitates were probed
for the presence of KGF or of NRP1 receptor by Western
blotting with the respective antibodies. KGF protein was
detected in NRP1 immunoprecipitates (Figure 8(c)) after
KGF treatment, thus indicating that KGF and NRP1 are able
to interact in ASCs. Such data prompted us to investigate the
possible involvement of NRP1 in ERK activation induced by
KGF. For this purpose, we downregulated the expression of
NRP1 in ASCs by means of a specific siRNA (siNRP). The
efficiency of NRP1 silencing in ASCs treated or not with
KGF for 5min was assessed by Western blot with an anti-
NRP1 antibody. Tubulin was used to assess the equal loading
(Figure 8(d)). NRP1 silencing was achieved with an efficiency
of about 70–80%, in both untreated and KGF-treated cells
(0.3-fold and 0.2-fold, resp., P < 0 0005), with respect to
treatment of cells with control siRNA (siNC) (Figure 8(d)).
In this case, we did not observe a significant decrease of
NRP1 protein levels after treatment with KGF for 5′, as pre-
viously shown for FGFR2 (Figure 7(a)). To better address this
point, since such a phenomenon would be expected if NRP1
functions as a receptor for KGF in ASCs, we performed time
course experiments to assess the protein levels of FGFR2 and
NRP1 after KGF treatment. Cells were treated with KGF for
5′, 15′, 30′, 1 h, 2 h, and 3h and then subjected to WB anal-
ysis for FGFR2 and NRP1 (Figure S1). We observed, as
expected, a significant decrease of FGFR2 levels just after
5′ of treatment (P < 0 0005), in accordance to what was
previously shown in Figure 7(a), then FGFR2 levels remains
significantly lower than those of untreated cells until 2 h of
treatment (P < 0 0005). Concerning NRP1, we observed,
although to a lesser extent and starting at longer time of
KGF exposure, a significant decrease of its expression after
15′ and 30′ of KGF treatment (P < 0 0005 and P < 0 005,
resp.). Therefore, the data obtained from time course exper-
iments are not in conflict with a potential role of NRP1 as
KGF receptor.
Then, we analyzed ERK activation induced by KGF in
NRP1-silenced cells. As shown in Figure 8(e), NRP1 down-
regulation significantly inhibited KGF-dependent ERK phos-
phorylation (1.0-fold for siNRP versus 1.3-fold for siNC). To
further assess NRP1 role in KGF-mediated signaling path-
ways, we analyzed phosphorylation of ERK, p38MAPK, and
Akt in NRP1-silenced cells at 30min of KGF treatment (since
previous experiments indicated a stronger pathway activa-
tion at this time point, see Figures 3 and 5). As reported in
Figure 9, we first assessed the efficiency of NRP1 silencing
in ASCs treated or not with KGF for 30min by Western blot
with an anti-NRP1 antibody. Tubulin was used to assess the
equal loading (Figure 9a). NRP1 silencing was achieved in
both untreated and KGF-treated cells (0.4-fold and 0.3-fold,
resp., P < 0 05), with respect to treatment of cells with control
siRNA (siNC). After NRP1 silencing, we observed a signifi-
cant reduction in KGF-induced activation of ERK (0.4-fold
for siNRP versus 1.9-fold for siNC), p38 (1.0-fold for siNRP
versus 1.9-fold for siNC), and Akt (0.6-fold for siNRP
versus 2.1-fold for siNC).
In conclusion, NRP1 seems to be directly responsible
for KGF-dependent pathway activation in ASCs, thus sug-
gesting its role as an alternative receptor for this growth
factor in these cells.
3.7. FGFR2-IIIb and NRP1 Expression during ASC
Adipogenesis. To assess the role of FGFR2-IIIb and NRP1
in adipogenesis, we induced our cells through adipogenic dif-
ferentiation by means of ADM medium and assessed the
transcript levels of both receptors in ASCs on several differ-
entiation times (0, 1, 2, 3, 7, 14, and 21 days) by qRT-PCR
(Figure 10). We found that FGFR2-IIIb expression
(Figure 10(a)) started to increase at day 3 of ASC differentia-
tion. In particular, we observed maximal upregulation in
middle-late differentiation (day 7, 5.7-fold increase, P <
0 05, and day 14, 6.7-fold increase, P < 0 005, resp.). As for
NRP1 (Figure 10(b)), its expression is holding steady during
all the differentiation process, with a slight increase peaking
at days 2 and 3 of adipogenic induction (1.3-fold increase),
thus suggesting a potential role of NRP1 in the response
of ASCs to endogenous KGF upregulation in early steps of
adipogenesis (see Figure 2(b)).
4. Discussion
The present work provides a novel insight into the role of
KGF in human adipogenesis of ASCs. It is well known that
ASCs, as well as bone marrow stem cells (BMSCs), release
soluble paracrine factors, including KGF, which are crucial
for the usefulness of these cells in therapeutic strategies to
restore structure and function of epithelial tissues. However,
at present, there is no evidence of a direct effect of KGF on
BMSCs. Interestingly, recent evidence indicates a role of
KGF in the differentiation of human umbilical cord-derived
mesenchymal stem cells (hUC-MSCs) into sweat gland-like
cells (SGCs), with potential implications in the field of regen-
eration of destroyed sweat glands and injured skin [36].
Moreover, a role of KGF in promoting proliferation path-
ways on murine preadipocytes [21], and in inducing the
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expression of key regulators of adipogenesis in alveolar
type II cells [22], has been previously reported. However,
the role of KGF in human ASC proliferation and adipogene-
sis still needs to be elucidated. In contrast to what observed in
murine preadipocytes [21], we demonstrated a significant
change in levels of KGF mRNA expression throughout ASC
adipogenic differentiation, with a peak at day 1 of differenti-
ation. This observation suggests that the upregulation of KGF
expression might be required for the proper induction of
ASC differentiation and prompted us to further investigate
the role of KGF in adipogenesis.
Since an effect of KGF on preadipocytes proliferation
has been previously demonstrated in a murine model
[21], we determined whether KGF could also induce ASC
proliferation. We decided to analyze the activation of the
extracellular signal-regulated kinase (ERK) pathway and the
p38MAPK pathway, since they are both indicated as required
not only for mesenchymal cell proliferation but also for the
mitotic clonal expansion that represent the first step of adi-
pogenesis [37, 38]. Based on our results, we suggest that
KGF might promote the proliferation of ASCs and the
mitotic clonal expansion to initiate adipogenesis through
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Figure 8: Effect of NRP1 silencing on KGF-mediated phosphorylation of ERK. Expression of NRP1 assessed by PCR (a) and Western blot
analysis (b) on ASC whole cell lysates. MDA-MB-231 cells were used as positive control for NRP1 expression. GAPDH mRNA expression
and blotting with anti-tubulin antibody served as loading control for PCR and Western blot analysis, respectively. The images are
representative of at least three independent experiments. (c) Coimmunoprecipitation assay was performed to study in vivo interaction
between KGF and NRP1 proteins. ASCs, untreated or treated with 20 ng/ml KGF for 5min, were immunoprecipitated with anti-NRP1
antibody and blotted with anti-FGF7 antibody. Western blot with anti-NRP1 antibody was used as loading control. (d) ASCs transfected
with NRP1-specific siRNA (siNRP) or nonspecific control siRNA (siNC), treated or not with 20 ng/ml KGF for 5min at 37°C, were lysed,
and NRP1 expression was analyzed by immunoblotting with anti-NRP1 antibodies. siNRP induced a marked reduction in NRP1
expression in both untreated and KGF-treated cells. Western blot with anti-tubulin antibodies was used as loading control. (e) The same
lysates were analyzed by immunoblotting with anti-phospho-ERK antibody. Transfection with siNRP significantly inhibits ERK
phosphorylation induced by KGF treatment. The levels of total ERK were assessed by Western blot with anti-ERK1/2 antibodies. The
intensity of the bands was evaluated by densitometric analysis; the values from a representative experiment were normalized, expressed as
fold increase with respect to the untreated siNC sample and reported as a graph. ∗P < 0 05 and ∗∗∗P < 0 0005.
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activation of ERK and p38MAPK pathways. Moreover, in
contrast with what observed by Zhang et al. [21], we demon-
strated that in human ASCs, proliferation and differentiation
are not mutually exclusive, since KGF is also able to promote
adipogenic differentiation. This double role in adipogenesis
has been previously demonstrated also for other growth fac-
tors and receptors, such as members of the Notch family and
of the FGF family [5, 12, 39].
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Figure 9: Effect of NRP1 silencing on KGF-mediated phosphorylation of ERK, p38, and Akt. (a) ASCs transfected with NRP1-specific siRNA
(siNRP) or nonspecific control siRNA (siNC), treated or not with 20 ng/ml KGF for 30min at 37°C, were lysed, and NRP1 expression was
analyzed by immunoblotting with anti-NRP1 antibodies. siNRP induced a marked reduction in NRP1 expression in both untreated and
KGF-treated cells. Western blot with anti-tubulin antibodies was used as loading control. (b) The same lysates were analyzed by
immunoblotting with anti-phospho-ERK antibody. Transfection with siNRP significantly inhibits ERK phosphorylation induced by KGF
treatment. The levels of total ERK were assessed by Western blot with anti-ERK1/2 antibodies. (c) Phosphorylation of p38 was assessed by
Western blot analysis with a phospho-specific p38 monoclonal antibody (pp38). Levels of total p38 were assessed by blotting with a p38-
specific antibody and served as loading control. (d) Phosphorylation of Akt was assessed by Western blot analysis with a phospho-specific
Akt monoclonal antibody (pAkt). Levels of total Akt were assessed by blotting with an Akt-specific antibody and served as loading
control.The intensity of the bands was evaluated by densitometric analysis; the values from a representative experiment were normalized,
expressed as fold increase with respect to the untreated siNC sample and reported as a graph. ∗P < 0 05 and ∗∗P < 0 005.
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However, the role of ERK and p38MAPK pathways in
adipogenesis is still controversial. In the case of ERK, its
activation seems to be necessary for the initial proliferative
step, but the pathway needs to be shut off to allow proper
differentiation [38]. Our data are consistent with this
observation, since we demonstrated that KGF induces only
transient ERK activation, in which phosphorylation is no
longer detectable after 24 h of KGF treatment. Concerning
p38MAPK pathway, opposing roles in adipocyte differentia-
tion have been described, but Aouadi et al. demonstrated a
positive role of this pathway in human adipogenesis through
regulation of adipogenic transcription factors [40]. There-
fore, our evidence of p38MAPK activation induced by KGF
is not in contrast with a role of this growth factor in ASC
differentiation. Moreover, this role is sustained by our obser-
vation of KGF-mediated stimulation of PI3K/Akt and Rb
pathways, which are known to be important for adipo-
genic differentiation [41, 42]. In particular, it has been
reported that Akt plays a role in adipogenesis in both
murine 3T3-L1 preadipocyte [43] and human ASCs [44].
Concerning the retinoblastoma protein Rb, its role in
adipogenesis is complex. Phosphorylation-dependent inac-
tivation of Rb permits progression through mitotic clonal
expansion, by releasing the members of the E2F family of
transcription factors [19]. However, Rb has also an impor-
tant role in cell cycle exit, as well as its interaction with
members of the C/EBP family of transcription factors. In
particular, Rb has been demonstrated to stimulate adipo-
genesis though activation of C/EBPα [45]. Early alterations
in Rb phosphorylation may be important for the antiadi-
pogenic effect of macrophage-secreted factors on 3T3-L1
adipocyte differentiation [46]. Other studies indicate that
pRb acts as a molecular switch determining white versus
brown adipogenesis, suggesting the function of Rb phos-
phorylation as a key cell cycle regulator in adipocyte line-
age commitment and differentiation [47]. In addition, it is
known that p38 activation can mediate an increase in the
phosphorylation of Rb [48]. Therefore, our data on Rb
phosphorylation are consistent with the observed activation
of p38MAPK pathway.
Our approach to assess KGF role in adipogenic differen-
tiation took in consideration also the evaluation of neutral
lipids. De novo lipid biosynthesis is controlled by sterol reg-
ulatory element-binding proteins (SREBPs), which are not
only generally activated in response to changes in intracellu-
lar and membrane levels of fatty acids and cholesterol but
also strongly induced during adipogenic differentiation, since
cholesterol accumulation is required very early during adipo-
genesis, in preparation for triglyceride synthesis and lipid
droplet formation [49]. Moreover, previous works demon-
strated a role of KGF in lipid metabolism, both in vitro on
a pulmonary epithelial cancer cell line [22] and in vivo in a
rat model [50]. In agreement with these data and with our
initial hypothesis, we were able to demonstrate a KGF-
dependent increase in neutral lipids (cholesterol, cholesterol
esters, and tryglicerides), suggestive of a preparative step to
initiate adipogenesis. Moreover, we observed that KGF treat-
ment during adipogenesis was able to increase cell differenti-
ation, determined as increased amount of oil red O stained
lipid droplets, increased amount of mature adipocytes
expressing FABP4 protein and higher expression of FABP4
mRNA in KGF-treated cells with respect to untreated cells.
However, we were able to detect only a slight increase in
PPARγ expression in KGF-treated cells at the end of differen-
tiation. Since PPARγ upregulation is a late event in adipogen-
esis, we can hypothesize that in the advanced steps of this
process, the effect of exogenous KGF might be partially
masked by the upregulation of endogenous KGF that occur
during differentiation.
It is known that FGFR2 gene is subjected to an alternative
splicing to obtain the FGFR2-IIIc isoform, generally
expressed in mesenchymal cells, or the FGFR2-IIIb isoform
(also called KGFR), preferentially found in epithelial cells.
Importantly, the only study reporting an effect of KGF on
adipose cells failed to detect the expression of FGFR2-IIIb,
the only known receptor that supports KGF signaling
[21], suggesting that the effects of KGF on preadipocytes
might be mediated through an unknown receptor rather
than FGFR2-IIIb. Such hypothesis is also proposed by
another study indicating KGF proliferative effect on
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Figure 10: qRT-PCR analysis of FGFR2-IIIb (a) and NRP1 (b) mRNA expression in ASCs at different times of adipogenic differentiation.
Relative mRNA levels at days 1, 2, 3, 7, 14, and 21 of adipogenic differentiation are shown as fold value of the level of mRNA in
undifferentiated cells (day 0). Each experiment was performed in triplicate, and mRNA levels were normalized to PPIA mRNA expression.
Error bars represent standard deviations. ∗P < 0 05 and ∗∗P < 0 005.
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endothelial cells derived from small vessels, which do not
express FGFR2-IIIb [51]. However, since further studies
demonstrated the expression of FGFR2-IIIb in vascular
smooth muscle cells [52], we decided to assess FGFR2-
IIIb expression in human ASCs. Our data demonstrated
for the first time that ASCs, despite their mesenchymal ori-
gin, express a low amount of FGFR2-IIIb transcript and
protein. Nevertheless, the open question was to determine
if such FGFR2-IIIb was able to function even if expressed
to a limited extent. To this aim, we took into account the
activation of ERK, the main signaling pathway downstream
KGF. Silencing of FGFR2 expression by means of small
interfering RNA did not determine any variation of ERK
phosphorylation, thus allowing us to conclude that FGFR2-
IIIb is not responsible for KGF-mediated signaling pathway
activation in ASCs. Such conclusion is supported by the
known efficacy of FGFR2-IIIb silencing in the reduction of
KGF effects on silenced cells, as previously demonstrated by
our group [33].
Exploring the hypothesis of a nonclassical KGF receptor,
we focused on NRP1, since it is indicated as a potential KGF
interactor. Coimmunoprecipitation experiments allowed us
to demonstrate that NRP1 is able to bind KGF in ASCs.
Moreover, besides its role as receptor for class 3 semaphorins,
NRP1 is also considered a coreceptor for some growth fac-
tors, such as VEGF or PDGF. Most data indicate that it lacks
a defined signaling activity, but recent evidence obtained in
melanoma cells has suggested that NRP1 is able to activate
VEGF-mediated signal transduction pathways also indepen-
dently of VEGFR-2 expression [25]. Consistent with this
data, the results of our study show that the expression of
NRP1 is necessary and sufficient for KGF-mediated activa-
tion of ERK, p38, and Akt pathways, thus indicating this
molecule as a previously unrecognized nonclassical receptor
for KGF. Interestingly, we found a differential expression of
FGFR2 and NRP1 upon KGF treatment in time course exper-
iments (see Figure S1). In particular, NRP1 downregulation
was found to be less consistent than that of FGFR2, and
limited to 15–30min of KGF treatment. However, it is
known that ligand binding should not necessarily induce
receptor degradation. In fact, also for FGFR2 itself, it has
been previously demonstrated that the receptor can have
an alternative fate depending on the ligand, since it is ubi-
quitinated and degraded after KGF treatment but not after
FGF10 treatment, probably due to a different regulation of
receptor endocytic transport [53]. In the future, it will be
interesting to investigate NRP1 intracellular fate upon treat-
ment with KGF.
The evaluation of FGFR2-IIIb and NRP1 expression
levels during adipogenesis represent a further confirmation
of this hypothesis. In fact, we observed that endogenous
KGF levels in differentiating ASCs increased in the first step
of adipogenesis (days 1 and 2, see Figure 2), but at this time
point, FGFR2-IIIb expression was still at basal levels, corre-
sponding to a very low amount of protein (see Figure 6).
The consistent amount of NRP1 protein in undifferentiated
ASCs (see Figure 8(b)) and its further increase in the first
days of adipogenesis (see Figure 10) support our hypothesis
that NRP1 might mediate FGF7 activities during clonal
expansion of ASCs, while FGFR2-IIIb mediates FGF7 action
subsequently (maybe in association with NRP1 as a corecep-
tor). Of course, to definitely validate this working model, our
future work will be dedicated to perform stable knockdown
of FGFR2-IIIb and NRP1 in ASCs subjected to adipogenic
differentiation.
5. Conclusions
Our study aimed to assess the role of KGF in human adipo-
genesis, in terms of proliferation and cell signaling activation.
We believe that the discovery of an increase in KGF expres-
sion during adipogenic differentiation could contribute to a
better understanding of the molecular bases of human adipo-
genesis, with potential implications for the therapeutical
application of ASCs for regenerative medicine, as well as for
the introduction of novel therapeutic strategies for obesity
and other disorders related to alteration of lipid metabolism.
Future work will be dedicated to better assess the role of KGF
in adipogenesis, by means of approaches involving knock-
down of KGF protein expression in ASCs and subsequent
evaluation of adipogenic differentiation.
Moreover, the discovery of the role of NRP1, a widely
expressed molecule, as a nonclassical KGF receptor indi-
cates that its effects might be not limited to the epithelial
tissues. Therefore, a deeper investigation of the specific con-
tribution of the canonical receptor FGFR2-IIIb and the
alternative receptor NRP1 to KGF signaling in different cel-
lular contexts could contribute to better understand a num-
ber of physiological and pathological processes involving
various tissues and organs.
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The intensity of the bands was evaluated by densitometric
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bars represent standard deviations. ∗∗P < 0 005 and ∗∗∗P <
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